^
    15h
    Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Case Comprehensive Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    6d
    Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) (clinicaltrials.gov)
    P=N/A, N=42, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    7d
    Post Marketing Study on Pluvicto in Korea (clinicaltrials.gov)
    P=N/A, N=278, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2027 --> Mar 2029 | Initiation date: Oct 2024 --> May 2025 | Trial primary completion date: Jul 2027 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date • Real-world evidence • Real-world
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    8d
    A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (clinicaltrials.gov)
    P1, N=106, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    12d
    A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    17d
    A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=27, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    17d
    [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Pentixapharm AG | Trial completion date: Apr 2026 --> Mar 2028 | Trial primary completion date: Dec 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    17d
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China (clinicaltrials.gov)
    P=N/A, N=100, Enrolling by invitation, GrandPharma (China) Co., Ltd.
    New trial
    |
    SIR-Spheres (yttrium-90 microspheres)
    17d
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Sep 2024 --> Jan 2025
    Trial initiation date
    |
    Solucin (177Lu-edotreotide)
    18d
    Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients. (PubMed, EJNMMI Rep)
    Our exploratory analysis provides preliminary results showing that imaging indices of inter- and intra-tumor heterogeneity from pretreatment PET/CT images may potentially predict treatment efficacy in NET patients undergoing [177Lu]Lu-DOTA-TATE therapy. However, prospective evaluation in a larger cohort is needed to further assess whether a comprehensive characterization of tumor heterogeneity within a patient can help guide treatment decisions.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    20d
    A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jan 2027 --> Dec 2024 | Trial primary completion date: Jan 2027 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    20d
    Intratumoral Distribution of [177Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer. (PubMed, Cancer Biother Radiopharm)
    Regrowth of the tumor post-[177Lu]Lu-PSMA-617 administration creates Ki67+/PSMA+ areas that have no radioactivity uptake and need additional therapy fractions. The identical intratumoral distribution of [177Lu]Lu-PSMA-617 and PSMA-targeted PET-tracers indicate that these will reveal the areas inside the tumor targeted by RPT at least at 1 h p.i.
    Preclinical • Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    22d
    18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer (clinicaltrials.gov)
    P4, N=15, Recruiting, VA Greater Los Angeles Healthcare System
    New P4 trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    22d
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients with Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TheraSphere (yttrium 90 microspheres)
    22d
    VOYAGER: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Boston Scientific Corporation | Suspended --> Active, not recruiting
    Enrollment closed
    |
    TheraSphere (yttrium 90 microspheres)
    23d
    PENTILULA: Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/refractory CXCR4+ Acute Leukemia. (clinicaltrials.gov)
    P1/2, N=21, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Oct 2027
    Enrollment open • Trial completion date • Trial primary completion date
    27d
    PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects. (PubMed, Radiographics)
    The U.S. Food and Drug Administration approval of 177Lu-PSMA-617 marked a substantial advancement in the treatment paradigm of metastatic castration-resistant prostate cancer, based on the VISION trial that showed improved overall survival and quality of life compared with those for standard care...This review underscores the role of PSMA radioligand therapy in the evolving landscape of prostate cancer treatment and its promise for improving patient outcomes.
    Review • Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    28d
    Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. (PubMed, J Neuroendocrinol)
    Peptide receptor radionuclide therapy (PRRT) using [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) represents an established treatment modality for somatostatin receptor-positive, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NET) of grade 1 or 2...The results of these studies are likely to help address existing knowledge gaps in the coming years. This review describes the clinical practice, recent developments and future treatment options of PRRT in patients with grade 1 and 2 GEP NET.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    29d
    PSMA-617-100: Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer (clinicaltrials.gov)
    P1, N=99, Recruiting, Endocyte | N=60 --> 99
    Enrollment change
    |
    abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • AAA817
    29d
    A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Blue Earth Therapeutics Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    Developing a peripheral blood RNA-seq based NETseq ensemble classifier: A potential novel tool for non-invasive detection and treatment response assessment in neuroendocrine tumor patients receiving 177Lu-DOTATATE PRRT. (PubMed, J Neuroendocrinol)
    The NETseq ensemble classifier identified PRRT-naïve GEP-NETs with high accuracy (≥92%) and demonstrated a potential role in early treatment response monitoring in the PRRT setting. This blood-based, non-invasive, multi-analyte molecular method could be developed as a valuable adjunct to conventional methods in the detection and treatment response assessment in NET patients.
    Journal
    |
    CHGA (Chromogranin A)
    |
    Lutathera (lutetium Lu 177 dotatate)
    1m
    Toxicity manifestations encountered in peptide receptor radionuclide therapy setting. (PubMed, J Neuroendocrinol)
    Potential high-risk factors in order to treat effectively and prevent these toxicities in NET patients are presented including the management strategy. This review also discusses novel insights, perspectives, and recent advancements in predicting, preventing, and managing toxicity associated with PRRT, while offering prospective future research directions to minimize clinical toxicity and maximize the therapeutic benefits of PRRT as a treatment strategy for NET patients.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    1m
    Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Nationwide Children's Hospital | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)
    1m
    LuTectomy: Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Peter MacCallum Cancer Centre, Australia | Trial completion date: Dec 2023 --> Aug 2025
    Trial completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy. (clinicaltrials.gov)
    P1, N=65, Recruiting, University of Michigan Rogel Cancer Center | N=45 --> 65
    Enrollment change
    |
    TheraSphere (yttrium 90 microspheres)
    3ms
    Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia (clinicaltrials.gov)
    P=N/A, N=7, Terminated, Northwestern University | N=20 --> 7 | Trial completion date: Apr 2025 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Apr 2024; Low enrollment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    3ms
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Jun 2024 --> Sep 2024
    Trial initiation date
    |
    Solucin (177Lu-edotreotide)
    4ms
    MANDARIN (S6371) (clinicaltrials.gov)
    P3, N=92, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Dec 2025
    Enrollment closed • Trial primary completion date
    |
    cisplatin • TheraSphere (yttrium 90 microspheres)
    4ms
    START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
    P3, N=300, Recruiting, Lund University Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    SSTR (Somatostatin Receptor)
    |
    capecitabine • Solucin (177Lu-edotreotide)
    4ms
    DOORwaY90: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Sirtex Medical | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SIR-Spheres (yttrium-90 microspheres)
    4ms
    LUFOR: "Receptor Radionuclide Therapy With 177Lu-DOTATOC (clinicaltrials.gov)
    P2, N=100, Recruiting, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    Solucin (177Lu-edotreotide)
    5ms
    177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. (PubMed, Q J Nucl Med Mol Imaging)
    The tumor AD that was reported during treatment with 177Lu-SSTR-RT in refractory meningioma patients is generally low. Harmonization of the methodology for dosimetry calculations is needed to compare the different reported values and optimize treatment at the individual level.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    5ms
    DOORwaY90: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Sirtex Medical | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    SIR-Spheres (yttrium-90 microspheres)
    5ms
    Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study. (PubMed, Oncologist)
    Careful patient selection, including consideration of the prognostic factors ECOG, baseline CEA, and KRAS status, sets outcome expectations in patients with colorectal liver metastases suitable for TARE/Chemo as second-line treatment (Trial Registry Number: NCT01483027).
    Journal • HEOR
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    TheraSphere (yttrium 90 microspheres)
    7ms
    Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1/2 trial
    |
    TheraSphere (yttrium 90 microspheres)
    7ms
    ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)
    P2, N=100, Recruiting, Boston Scientific Corporation | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • TheraSphere (yttrium 90 microspheres)
    7ms
    Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia (clinicaltrials.gov)
    P=N/A, N=20, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TheraSphere (yttrium 90 microspheres)
    7ms
    VOYAGER: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (clinicaltrials.gov)
    P=N/A, N=36, Suspended, Boston Scientific Corporation | Recruiting --> Suspended
    Trial suspension
    |
    TheraSphere (yttrium 90 microspheres)
    8ms
    LUCIDA_2: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, FutureChem | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    [177Lu]ludotadipep (177 Lu-FC705)
    8ms
    LUCIDA: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application (clinicaltrials.gov)
    P1/2, N=26, Recruiting, FutureChem | Phase classification: P2a --> P1/2 | Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    FOLH1 positive
    |
    [177Lu]ludotadipep (177 Lu-FC705)
    8ms
    TACOME: Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver (clinicaltrials.gov)
    P=N/A, N=202, Completed, Ankara University | Not yet recruiting --> Completed | N=350 --> 202 | Initiation date: Sep 2023 --> Jan 2024
    Trial completion • Enrollment change • Trial initiation date
    |
    TheraSphere (yttrium 90 microspheres)
    8ms
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Recruiting, Boston Scientific Corporation | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)